Status:

COMPLETED

A Study of Fibrocaps™ in Surgical Bleeding

Lead Sponsor:

Mallinckrodt

Conditions:

Mild or Moderate Surgical Bleeding

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to confirm the superiority of Fibrocaps plus gelatin sponge, as compared to gelatin sponge alone, for achieving hemostasis. The investigational products were used in part...

Eligibility Criteria

Inclusion

  • Has signed an institutional review board/independent ethics committee (IRB/IEC)-approved informed consent document
  • Is undergoing one of the 4 surgical procedures described
  • Is at least 18 years old at time of consent
  • If female and of child-bearing potential, has negative pregnancy test during screening and is not breast-feeding
  • If able to reproduce, agrees to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits when engaging in heterosexual intercourse
  • Has not received blood transfusion between screening and study treatment
  • Has mild to moderate surgical bleeding
  • Does not have intra-operative complications
  • Has not used a topical hemostat containing thrombin prior to study treatment
  • Has an approximate bleeding site surface area of less than or equal to 100 cm\^2

Exclusion

  • Has known antibodies or hypersensitivity to thrombin or other coagulation factors
  • Has history of heparin-induced thrombocytopenia (only for vascular subjects where heparin use is required)
  • Has known allergy to gelatin sponge
  • Is unwilling to receive blood products
  • Has liver enzymes appropriate for the study, considering their disease
  • Has appropriate level of platelets per liter (PLT/L) during screening
  • Has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the Investigator, or baseline abnormalities during screening that are not explained by current drug treatment (e.g., warfarin, heparin)

Key Trial Info

Start Date :

May 21 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2013

Estimated Enrollment :

721 Patients enrolled

Trial Details

Trial ID

NCT01527357

Start Date

May 21 2012

End Date

June 1 2013

Last Update

December 18 2019

Active Locations (48)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 12 (48 locations)

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

2

Cardio-Thoracic Surgeons, PC

Birmingham, Alabama, United States, 35242

3

University of Southern California, Keck School of Medicine

Los Angeles, California, United States, 90033

4

University of Southern California/Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033